Eyenovia Inc Stock Price, News & Analysis

Eyenovia, Inc. (NASDAQ: EYEN) has successfully closed its public offering of 12,850,000 shares of common stock at $0.40 per share, raising approximately $5.14 million in gross proceeds. The company plans to use the funds for commercializing Mydcombi and clobetasol propionate, completing the CHAPERONE pediatric myopia clinical study, and for working capital and general corporate purposes, including potential debt repayment. Dawson James Securities, Inc. acted as the placement agent for the offering, which was conducted under Eyenovia's previously filed shelf registration statement.

Eyenovia (NASDAQ: EYEN), a commercial-stage ophthalmic company, has announced the pricing of a $5.14 million public offering. The company will sell 12,850,000 shares of common stock at $0.40 per share, with the closing expected on August 22, 2024. Dawson James Securities, Inc. is acting as the placement agent. Eyenovia plans to use the net proceeds to fund commercialization activities for Mydcombi and clobetasol propionate, complete the CHAPERONE pediatric myopia clinical study, and for working capital and general corporate purposes, including potential repayment of existing debt. The offering is made pursuant to Eyenovia's previously filed shelf registration statement on Form S-3.

Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company, has announced its intention to offer and sell shares of common stock (or pre-funded warrants) in a best efforts public offering. The offering's size and terms are subject to market conditions. Eyenovia plans to use the net proceeds for:

• Commercialization of Mydcombi and clobetasol propionate
• Completion of the CHAPERONE pediatric myopia clinical study
• Working capital and general corporate purposes
• Potential repayment of existing debt

Dawson James Securities, Inc. is acting as the sole placement agent. The offering is being made through a shelf registration statement and will be available via a prospectus supplement and accompanying prospectus.

Eyenovia Inc. (NASDAQ: EYEN), an ophthalmic technology company, announced its participation in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference on August 15th, 2024. The company's pre-recorded presentation will be available on-demand starting at 7:00 am EDT on the conference day.

Eyenovia is known for commercializing Mydcombi™, an ophthalmic spray for mydriasis, and clobetasol propionate ophthalmic suspension for postsurgical inflammation and pain. They are also developing the Optejet® device for pediatric progressive myopia and dry eye treatments, with potential for out-licensing in additional indications.

Investors and interested parties can access the presentation by registering for the conference. Virtual 1x1 meetings with Eyenovia management can be arranged through H.C. Wainwright representatives.

Eyenovia Inc (NASDAQ: EYEN) reported its Q2 2024 financial results and provided a corporate update. Key highlights include:

1. Plans for validation of the Gen-2 Optejet® device with 2025 regulatory submission for Mydcombi™.
2. Advancement of Phase 3 CHAPERONE study for MicroPine in pediatric progressive myopia.
3. Collaboration agreements with Formosa, Senju, and SGN for dry eye disease treatments.
4. Expanded Mydcombi sales to 63 new offices in Q2, targeting 263 by Q3 end.

Financially, Eyenovia reported a net loss of $11.1 million ($0.21 per share) for Q2 2024, compared to $6.2 million ($0.16 per share) in Q2 2023. The company had $2.3 million in cash as of June 30, 2024, excluding $5.8 million from subsequent equity offerings.

Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic company with two FDA-approved products and a late-stage asset in pediatric progressive myopia, has announced its plans to release financial results for the second quarter ended June 30, 2024 on Monday, August 12th, 2024, after market close. The company will host a conference call and webcast at 4:30 p.m. ET to review the financial and operating results.

Investors can participate by dialing 1-877-407-9039 (domestic) or 1-201-689-8470 (international) with Conference ID# 13747356. A live webcast will be available on the company's website, and the event will be archived for one year after the live webcast.

Eyenovia (NASDAQ: EYEN) and Formosa Pharmaceuticals (TWO:6838) have initiated co-development of clobetasol propionate ophthalmic suspension (0.05%) for treating acute dry eye disease in the U.S. This collaboration expands their existing agreement from February 2023. The product will combine clobetasol propionate, a potent steroid FDA-approved on March 4, 2024, with Eyenovia's Optejet® device.

The U.S. market for topical ocular steroids and steroid combinations is worth approximately $1.3 billion. This new indication could benefit millions experiencing dry eye flare-ups. The companies will share development costs and profits upon commercialization, pending due diligence and a definitive agreement.

Formosa Pharmaceuticals and Eyenovia have announced a collaboration to co-develop Clobetasol Propionate Ophthalmic Suspension 0.05% for the short-term relief of dry eye disease in the United States. This agreement expands their existing partnership from February 2023. Clobetasol propionate, a potent steroid, was FDA-approved on March 4, 2024, for reducing inflammation and pain associated with ocular surgeries. The additional acute dry eye indication could benefit millions experiencing flare-ups, as about 80% of dry eye patients suffer from flare-ups. Formosa's proprietary APNT® nanoparticle formulation platform enhances the drug's bioavailability, while Eyenovia's Optejet® dispenser technology offers advanced delivery. This collaboration aims to address a significant market, with approximately 2 million people in the US treated with prescription medications for dry eye.

Eyenovia (NASDAQ: EYEN) and SGN Nanopharma have announced a collaboration agreement to develop a novel treatment for chronic dry eye disease. The partnership aims to combine SGN's Micellar Nanoparticle Platform (MNP) cyclosporine formulation with Eyenovia's Optejet® dispenser. This collaboration targets the $3 billion U.S. addressable market for dry eye disease, affecting an estimated 35 million people.

Key points:

• SGN's MNP Cyclosporine showed superior results in clinical studies compared to current treatments
• Optejet dispenser delivers medication with 80% less drug volume, potentially improving tolerability
• The companies aim to create a 'best-in-class' therapy for the underserved dry eye market
• They plan to validate manufacturability and consult with the FDA for clinical development